Relationship of Cerebrospinal Fluid Vitamin B12 Status Markers With Parkinson's Disease Progression

the Parkinson Study Group—DATATOP Investigators

Research output: Contribution to journalArticle

Abstract

Background: Using blood specimens from untreated early Parkinson's disease (PD) patients from the DATATOP trial, we found that subjects in the low serum vitamin B12 tertile experienced greater annualized change in ambulatory capacity score, whereas those with moderately elevated (>15 μmol/L) total homocysteine had greater annualized declines in the Mini-Mental State Exam. Methods: In this this study we sought to determine whether levels of cerebrospinal fluid (CSF) B12 markers were also associated with progression of PD. Results: The annualized change in the UPDRS “walking” item, a component of the ambulatory capacity score, was worse in the low B12 tertile. No association with change in the Mini-Mental State Exam was seen for those 7% with the highest baseline CSF total homocysteine. Conclusions: In these untreated early-PD subjects, low CSF B12 predicted greater worsening of the UPDRS “walking” item, whereas CSF total homocysteine was not associated with progression of cognitive impairment. These findings extend and partially support our findings in serum.

Original languageEnglish (US)
JournalMovement Disorders
DOIs
StateAccepted/In press - Jan 1 2020

Keywords

  • cognitive impairment
  • CSF
  • cyanocobalamin
  • gait instability
  • hyperhomocysteinemia
  • vitamin B12

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Relationship of Cerebrospinal Fluid Vitamin B12 Status Markers With Parkinson's Disease Progression'. Together they form a unique fingerprint.

  • Cite this